newsfilter
← Latest News
GlobeNewswire·

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancerCRB-701 data for both indications is expected in mid-2026 with focus on